Efficacy of 2 Representative Topical Agents to Prevent Keloid Recurrence After Surgical Excision

J Oral Maxillofac Surg. 2017 Feb;75(2):401.e1-401.e6. doi: 10.1016/j.joms.2016.10.009. Epub 2016 Oct 25.

Abstract

Purpose: Keloids are difficult to remove successfully and there is no universally accepted treatment. After surgical excision of the keloid, there are various management methods for prevention of keloid recurrence, such as intralesional injection, radiation, and topical agents. A few studies have compared topical agents with other treatments. The aim of this study was to investigate effective topical agents for the prevention of recurrent keloid after surgical excision.

Materials and methods: Eligible articles were sought using core databases, including Medline, Embase, and Cochrane databases, up to April 2016. The predictor variables were mitomycin C (MC) and imiquimod cream treatment after keloid excision. The outcome variable was keloid recurrence rate.

Results: The search strategy identified 120 publications. After screening, 9 articles were selected for review. Articles were divided into 2 groups: MC and imiquimod cream. The recurrence rate after surgical excision in the MC group was estimated to be 16.5%, and that in the imiquimod cream group was estimated to be 24.7%.

Conclusion: If intralesional injection or radiation is not available, then MC or imiquimod 5% cream could be an effective alternative in preventing keloid recurrence.

Publication types

  • Review

MeSH terms

  • Administration, Cutaneous
  • Aminoquinolines / administration & dosage
  • Aminoquinolines / therapeutic use*
  • Dermatologic Agents / administration & dosage
  • Dermatologic Agents / therapeutic use*
  • Humans
  • Imiquimod
  • Keloid / drug therapy
  • Keloid / prevention & control*
  • Keloid / surgery
  • Mitomycin / administration & dosage
  • Mitomycin / therapeutic use*
  • Recurrence
  • Treatment Outcome

Substances

  • Aminoquinolines
  • Dermatologic Agents
  • Mitomycin
  • Imiquimod